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Abstract
Background: Tumor classification based on their predicted responses to kinase inhibitors is a major goal for advancing
targeted personalized therapies. Here, we used a phosphoproteomic approach to investigate biological heterogeneity
across hematological cancer cell lines including acute myeloid leukemia, lymphoma, and multiple myeloma.
Results: Mass spectrometry was used to quantify 2,000 phosphorylation sites across three acute myeloid leukemia,
three lymphoma, and three multiple myeloma cell lines in six biological replicates. The intensities of the
phosphorylation sites grouped these cancer cell lines according to their tumor type. In addition, a
phosphoproteomic analysis of seven acute myeloid leukemia cell lines revealed a battery of phosphorylation sites
whose combined intensities correlated with the growth-inhibitory responses to three kinase inhibitors with
remarkable correlation coefficients and fold changes (> 100 between the most resistant and sensitive cells). Modeling
based on regression analysis indicated that a subset of phosphorylation sites could be used to predict response to
the tested drugs. Quantitative analysis of phosphorylation motifs indicated that resistant and sensitive cells differed in
their patterns of kinase activities, but, interestingly, phosphorylations correlating with responses were not on
members of the pathway being targeted; instead, these mainly were on parallel kinase pathways.
Conclusion: This study reveals that the information on kinase activation encoded in phosphoproteomics data
correlates remarkably well with the phenotypic responses of cancer cells to compounds that target kinase signaling and
could be useful for the identification of novel markers of resistance or sensitivity to drugs that target the signaling
network.
Background
Hematologic malignancies are a group of neoplastic
diseases that originate from the transformation of bone
marrow-derived cells. This group, which includes leuke-
mias, lymphomas, and myelomas, is extraordinarily
heterogeneous, which reflects the complexity of normal
hematopoiesis and the immune system [1]. Although
gene expression signatures can be used to classify malig-
nancies into subgroups [2-4], a system-level understan-
ding of the biochemical pathways (both signaling and
metabolic) responsible for tumor phenotypes requires
knowledge of signaling pathway activity, information
that cannot be provided by measuring mRNA or protein
expression alone [5,6], as enzyme expression does not
necessarily correlate with pathway activity [7].
Essentially all cancers are driven by deregulation of
protein kinase cascades downstream of growth factor,
antigen, and G protein-coupled receptors [8]. Conse-
quently, several kinase inhibitors that block cell transduc-
tion pathways overactive in cancer are already in the
clinic while others are undergoing pre-clinical or clinical
development. However, although clinical impact is
observed in some patients, many patients do not respond
to these therapies or subsequently develop resistance
[9,10]. The use of predictive biomarkers, or ‘companion
diagnostics’, is therefore important in individualizing
such targeted agents [11]. While the activity of the target
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kinase can in some instances predict response [12], this is
not always the case, as the activity of parallel pathways in
the network can contribute to resistance [13,14]. It could
therefore be envisaged that the analysis of kinase signal-
ing without a preconception of the pathways that may be
active could be advantageous in predicting responses to
kinase inhibitors.
Phosphorylation is a posttranslational modification
regulated by the activity of kinases and phosphatases. By
definition, each phosphorylation site is the result of a
kinase/phosphatase reaction pair. Changes in phosphor-
ylation status can alter many aspects of protein biology,
including their localization, protein-protein interactions,
stability, and enzymatic activity [15]. Although the infor-
mation coded by phosphorylation patterns has not been
completely deciphered, many phosphorylation sites can
be associated with the activity of a specific protein
kinase and thereby classified into signaling pathways
[16-18]. Thus, global analysis of protein phosphorylation
using quantitative techniques may in principle be trans-
lated into knowledge of the activation status of signaling
pathways. This information, in turn, could be used to
rationalize how the wiring of the kinase network contri-
butes to the phenotypic characteristics of different
tumors, such as aggressiveness, metastatic potential, and
sensitivity to therapy.
The application of new proteomic techniques for
phosphopeptide quantification is contributing to an
improved understanding of cancer cell biology [19-23].
Several techniques for quantitative proteomics have
been developed; these can be divided into those that
require labeling of proteins with stable isotopes (for
example, SILAC and iTRAQ) and those that do not
require labeling [24,25]. Approaches based on labeling
techniques usually detect a larger number of phospho-
peptides than those based on label-free approachesbe-
cause labeling techniques are compatible with extensive
fractionation prior to mass spectrometry analysis.
However, because of the time-consuming nature of such
analyses, studies based on labeling techniques normally
compare a small number of samples with no (or very
few) biological replicates, a feature that limit the statisti-
cal significance of the results. Therefore there is a trade-
off between the number of peptide/proteins identified
and samples that can be compared in a study. Label-free
approaches are preferred when the aim is to compare
large sample numbers and replicates [26,27] even
though the penetrance of the approach may not be as
large as when using techniques that allow extensive
fractionation before mass spectrometry analysis.
In the current study, label-free mass spectrometry
(MS) was first used to analyze the phosphoproteomes of
nine different hematological cancer cell lines. Unsuper-
vised analysis of the data based on principal component
analysis (PCA) and hierarchical clustering classified
these cell lines according to their pathological origin,
namely acute myeloid leukemia (AML), lymphoma, or
multiple myeloma. Through a lasso linear regression
analysis we assessed the potential of this data in predict-
ing the level of sensitivity of seven AML to three kinase
inhibitors: PI-103 (a PI3K/mTOR inhibitor), MEK-i, and
JAK-i. Finally we identified phosphopeptides whose
intensities across the cell lines correlated with the sensi-
tivity to three inhibitors. Our results revealed a battery
of phosphorylation sites whose intensities strongly
correlated with responses of our AML panel to the com-
pounds (with R > 0.9 and > 100-fold difference between
most sensitive and most resistant cell line). These data
therefore indicate that MS-based quantitative phospho-
proteomics has the potential to classify cell lines into
distinct subgroups according to their pathological origin
and to their sensitivity to drugs that target kinase signal-
ing. Phosphorylation sites that correlated with resistance
were enriched in basic and proline-directed motifs,
whereas those that correlated with sensitivity were
mainly acidic or hydrophobic containing, thus suggest-
ing that the relative activities of basophilic, proline
directed, and acidophilic kinases may determine
responses to the inhibitors. Therefore, the results of our
study indicate that unbiased profiling of phosphorylation
has the potential to stratify AML cells based on their
responses to signaling inhibitors because these responses
may be dependent on the combination of pathways
(both target and parallel) active in cells, rather than on
the activity of the target kinase/pathway only.
Results
Overview of protein phosphorylation in hematological
cancer cells
A group of nine different hematological cell lines, con-
sisting of three acute myeloid leukemia (AML), three
lymphoma, and three multiple myeloma cell lines (Addi-
tional file 1, Table S1), was selected for analysis using a
quantitative LC-MS/MS phosphoproteomics workflow
summarized in Additional file 2, Figure S1A. This
approach to quantify phosphorylation, which involves
comparing peak intensities of phosphopeptides calcu-
lated as the height and areas of ions extracted from
aligned chromatograms, has been independently vali-
dated by immunoblotting in our previous work that
showed that this methodology can be used to quantify
phosphopeptide levels with good precision and accuracy
[16,28]. The technique is similar to that used in other
laboratories [29-31].
Three biological replicates were analyzed on two sepa-
rate occasions to give a total of six replicates per cell
line, requiring 54 LC-MS/MS runs. The approach led to
the identification of 2,050 phosphopeptides in 1,664
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proteins (Additional file 3, Dataset 1). Given that phos-
phopeptides can contain more than one phosphorylation
site, in total we identified 2,434 unique phosphorylation
sites. Of these, the precise position of the modification
was ambiguous for 738 sites. The remaining 1,696 sites
(70% of total) were classified according to the amino
acid bearing the site of phosphorylation. Additional file
2, Figure S1B shows that 1,254 (74%), 344 (20%), and 98
(6%) of phosphorylation sites were on serine, threonine,
and tyrosine, respectively. These results are comparable
with the distribution of phosphorylation sites in HeLa
carcinoma cells and in platelets [32,33].
In order to further assess the nature of the phosphopro-
teomes identified in this study, we compared the assigned
gene ontologies (GO) of the phosphoproteins with those
proteins present in the whole human proteome (obtained
from the SwissProt database, Additional file 4, Figure S2).
Each protein was classified according to the three different
domains included in the gene ontology project [34],
namely (1) cellular component which describes the subcel-
lular localization of the identified protein (or its extracellu-
lar environment); (2) biological process which indicates
the biological function to which the gene product contri-
butes; and (3) molecular function which describes the
elemental activities of a gene product at a molecular level
[34]. The distributions of these domains in our phospho-
protein database were compared to those in the SwissProt
database (which lists all the known gene products and can
thus be considered to represent the whole human pro-
teome). The data show that phosphoproteins were on the
whole not biased towards any GO, in that the subcellular
distribution of phosphoproteins identified were similar to
those reported in the SwissProt database (Additional file 4,
Figure S2A). The minor differences in the proportion of
membrane proteins could be explained by the difficulty in
solubilizing membrane proteins with buffers compatible
with the rest of the workflow. We also observed that phos-
phoproteins located in the cytosol/cytoplasm and those
with roles in translation, cell cycle regulation, and prolif-
eration were well represented relative to the whole
proteome (Additional file 4, Figure S2A and S2B). Other
well represented phosphoproteins include those with
protein kinase activity and other enzymes (Additional file
4, Figure S2C).
Phosphoproteomics classified hematological cancer cells
according to pathology
We next asked whether quantitative phosphoproteomics
could be used to classify hematological cell lines accord-
ing to their pathological origin. Normalized peptide
intensities were used to calculate the overall fold differ-
ence (relative to the mean value across all samples) for
each phosphopeptide identified and quantified in our
study. These data were then subjected to principal
component analysis (PCA). When analyzing the nine
cell lines together, inspection of the PCA outputs (Fig-
ure 1A) revealed that principal component 1 (PC1) pro-
duced two clearly separated groups, one containing
AML cell lines and another containing lymphoma and
multiple myeloma cell lines, while principal component
2 (PC2) separated cells derived from lymphoma from
those that originated from multiple myeloma (Figure
1A). We also analyzed the phosphorylation data of each
cell line in three separate PCA plots corresponding to
the three different cancer types. Only data on the cell
lines of each different malignancy were included in each
particular PCA plot. These data, summarized in Figure
1B, revealed that cell lines within a given disease could
also be separated based on their phosphoprotein con-
tent, indicating global differences in phosphorylation
between cells of the same pathology with the exception
of RL and DoHH2 lymphoma cell lines which could not
be separated by PCA (Figure 1B).
The ability of phosphoproteomics to classify hemato-
logical cell lines was also assessed by unsupervised hier-
archical clustering. This analysis also classified the
samples into three main groups corresponding to AML,
lymphoma, and multiple myeloma, and clustered repli-
cates for each cell line within those groups. Interestingly
lymphoma and multiple myeloma cells were clustered
together, consistent with AML cells being the most dif-
ferentiated group (Figure 1C). This is consistent with
the data obtained by PCA (Figure 1A). Taken together,
the data in Figure 1 indicate that although there are dif-
ferences in global phosphoprotein abundance within cell
lines of the same pathology, the differences in the phos-
phoproteomes of hematological cancer cells are greater
across pathology groups than within a given disease.
Stringent statistical analysis (as indicated in materials
and methods) identified 609 phosphopeptides differentially
regulated in the AML cell lines, of which 544 showed
increased phosphorylation and 65 decreased phosphoryla-
tion, 46 were different in lymphoma cells (30 increased
and 16 decreased) and 53 in multiple myeloma (27
increased and 26 decreased) (Figure 1D). Representative
examples of phosphopeptides increased or decreased in
AML, lymphoma, and multiple myeloma cells are shown
in Additional file 5, Figure S3. Taken together, these data
show that label-free quantitative phosphoproteomic data
can be used to reproducibly classify hematological cancer
cell lines according to their pathological origin.
Phosphorylation patterns in hematological cancer cells
associated with sensitivity/resistance to kinase inhibitors
In order to assess whether phosphoproteomicscould also
be used to classify cells according to their responses to
kinase inhibitor treatment, we compared phosphoryla-
tion patterns with the sensitivity of a panel of seven
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AML cell lines (Additional file 1, Table S2) to a PI3K/
mTOR inhibitor (PI-103), a MEK-inhibitor (MEK-i), and
a JAK-inhibitor (JAK-i). Cell lines were ranked accord-
ing to the percentage reduction in MTS signals when
incubated with 1 μM PI-103, 1 μM JAK-i, or 10 μM
MEK-i (Figure 2). MTS measures mitochondrial redox
activity, a parameter that often correlates with cell viabi-
lity. In our assay a reduction in MTS signal as a func-
tion of compound treatment may be taken to indicate a
reduction in the number of viable cells relative to the
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Figure 1 Phosphoproteomics classify hematological cell lines according to their tissue origin. Phosphopeptides identified by LC-MS/MS
with Mascot and quantified with Pescal in nine hematological cell lines were analyzed by two different clustering tools. (a) Principal component
analysis (PCA) of all the cell lines based on the analysis of the most intense 1,500 phosphopeptides. (b) Independent PCA plots of cells
belonging to the same pathological group. (c) Unsupervised hierarchical clustering using Kendall’s tau coefficient to measure association
between peptides and arrays and complete linkage clustering to calculate distances between clusters; AML samples are highlighted in red,
lymphoma in blue, and multiple myeloma in green. Each replicate is shown separately and the cell line number is followed by the order in
which the samples were analyzed by LC-MS/MS. (d) Summary of phosphopeptides differentially regulated in AML, lymphoma, and multiple
myeloma cell lines with two-fold difference over mean expression and P < 0.05 after t-test and FDR multiple test correction.
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control as a combined action of the drugs in inhibiting
proliferation and inducing cell death.
We then performed phosphoproteomics analysis on
these cell lines (the data are shown in Additional file 6,
Dataset 2). These experiments were performed in three
independent cell cultures per cell line and further data
analysis was based on phosphopeptide intensities from
individual replicates rather than the averages values of
the three replicates.
Assessing the potential of phosphoproteomics data in
predicting drug responses
We assessed the ability of phosphoproteomics data in
predicting the drug sensitivity profiles of our panel of
cell lines against the three tested inhibitors through a
‘leave-one-cell-line-out’ (LOCLO) approach based on
lasso regression [55], detailed in the methods section.
For each of the three tested drugs, we trained seven dif-
ferent models by leaving out the samples corresponding
to each of the seven cell lines in turn, and composing
each time a test set with them. The trained models were
finally used to make predictions on the test set.
Each training phase was composed by a three-fold
cross validation estimation of the lasso shrinkage para-
meter (involving 18 of the corresponding training set
only) followed by an optimization phase of the regressor
coefficients (on the training set) and was repeated 20
times. Finally an average trained model was assembled
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Figure 2 Responses of hematological cell lines to kinase inhibitors. AML cells were exposed to 1 μM PI-103, 10 μM MEK-i, or 1 μM JAK-i for
72 h and viability measured by MTS and expressed as percentage to DMSO (control) treated cells. Cell lines were then ranked according to their
responses to the inhibitors. Values are mean ± SD (n = 4).
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across these 20 iterations and used to predict drug-
responses for the corresponding test set.
A scatter plot of the predicted viability scores for each
of the test set versus the observed ones is depicted in
Figure 3A. To make results comparable in this plot, test
set predictions were normalized together with the corre-
sponding training set predictions and for the same
reason, all the observed viability scores were normalized
drug-wisely. A remarkably high and statistically signifi-
cant values of Pearson correlation coefficient (R) were
measured between observed/predicted viability scores
summarizing response to treatment with PI-103
(R = 0.94, P value = 1.15 × 10-10) and JAK-i (R = 0.84, P
value = 1.53 × 10-6). When considered together, the
observed/predicted viability scores for these two drugs
was still high and significant (R = 0.72, P value = 8.77 ×
10-8) while the overall correlation considering all the
three drugs was weaker (R = 0.53, P value = 9.86 × 10-6)
and no statistically significant R was observed on the
MEK-i scores alone. Scatter plots for individual drugs,
with cell line identifiers and all the R scores and P values
are provided in Additional file 7, Figure 4.
Finally, for each of the three tested drugs, we deter-
mined a final descriptive model by pooling together (as
detailed in the method section) all the models generated
in the corresponding LOCLO iterations. These final
models, provided in Additional file 8, Dataset 3, con-
tained 33, 32, and 41 phosphopeptides (respectively for
PI-103, JAK-i, and MEK-i) that were contained in at
least one of the final models generated during the
LOCLO iterations together with their coefficient aver-
aged across the iteration and the frequency through
which this was different from zero (that is, percentage
of LOCLO iterations in which the phosphopeptide was
included in the model).
In Figure 3 (B, C, and 3D) we reported excerpts of the
final descriptive models including only regressors whose
inclusion frequency is > 50% (sufficiently stably included).
Taken together these results suggest that phosphopro-
teomics data have the potential to predict responses to
the analyzed compounds in cell line models and that a
relatively small core-set of phosphopeptides is strongly
associated to viability scores.
Identification of subsets of phosphorylation sites that
correlate with sensitivity
To complement the analysis based on LASSO, we also
performed a correlation study to identify further phos-
phopeptides associated with responses to the three
inhibitors. Figure 4A illustrates phosphopeptide inten-
sities showing stronger associations with resistance or
with sensitivity to PI-103. We observed that the
0
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correlations with responses were not always linear but
instead often followed an exponential trend. This is
illustrated in Figure 4B and 4C (left graphs) for phos-
phopeptides derived from NBEAL pT225 and DBNL
pT295 which showed the greater correlation with resis-
tance or sensitivity, respectively. Expressing normalized
peak heights as a function of cell viability in semi-
logarithmic scale produced a linear relationship
between viability and phosphopeptide intensities
(Figure 4B and 4C, right graphs) with R = 0.78 for
NBEAL and R = -0.74 for DBNL phosphopeptides,
consistent with the existence of an exponential rela-
tionship between viability and phosphopeptide intensi-
ties for these peptides.
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Figure 4 Correlating responses to PI-103 with phosphoproteomics data. The normalized intensities of phosphopeptides quantified across
seven AML cell lines were correlated with their responses to the inhibition of proliferation after exposure to 1 μM PI-103, as measured by cell
viability. (a) Phosphopeptides showing greater correlation with resistance or sensitivity to PI-103. (b) Relationship between normalized intensity of
phosphorylated NBEAL1 and responses to PI-103. (c) Relationship between normalized intensity of phosphorylated DBNL and responses to PI-
103. (d) Correlation of the sum of the intensities showing greater correlation with resistance. (e) Correlation of the sum of the intensities
showing greater correlation with sensitivity. (f) Correlation of the ratio between phosphopeptide intensities showing greater correlation to
resistance relative to those showing greater correlation with sensitivity. In each case, R refers to the Pearson correlation coefficient of the log2
transformed data; fold refers to the division of the intensities of the peptide group increased in the most resistant cell line by that of the most
sensitive cell line; open squares are individual data points of three biological replicates; blue diamonds are the averages of the three replicates.
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We also investigated whether a combination of several
phosphopeptides could be used to find associations
between our panel of AML cells and their response to PI-
103. As Figure 4D shows, the added intensities of the 10
phosphopeptides with greater correlation with the
responses to PI-103 (denoted as group 1 in Figure 4D)
showed a very strong correlation (R = 0.94) with the viabi-
lity of cells exposed to PI-103. As with the behavior of sin-
gle phosphopeptides, the correlation was more linear in
semi-log than in linear scale (Figure 4D). The sum of the
phosphopeptides with greater correlation with sensitivity
(denoted as group 2 in Figure 4E) also showed a linear
relationship with cell viability in semi-log scale (R = -0.94,
Figure 4E). Remarkably, the ratio of phosphopeptide inten-
sities that correlate with resistance (group 1) to those that
correlate with sensitivity (group 2) showed a Pearson score
of R = 0.99 with viability (Figure 4F). The differences in
combined phosphopeptide intensities between the most
resistant and most sensitive cell lines was 150-fold for the
group 1:group 2 ratio (Figure 4F) compared to just 23-fold
for group 1 (Figure 4D), indicating that the ratio of
phosphopeptide intensities that correlate with resistance
relative to those that correlate with sensitivity could be a
strong classifier for the stratification of AML cells based
on the likelihood that they respond to PI-103.
Phosphopeptide intensities were also correlated with
the responses to MEK-i and JAK-i. Phosphopeptides
showing the stronger association with resistance or sensi-
tivity to MEK-i are shown in Figure 5A. The added inten-
sities of phosphopeptides that correlated with resistance
(group 1) or sensitivity (group 2) are shown in Figure 5B
and 5C, respectively. As with the analysis of phosphopep-
tides correlating with responses to PI-103, the ratio of
group 1 to group 2 showed a greater linear correlation
(R = 0.95) and fold difference (284) between the most
sensitive and resistant cells to MEK-i (Figure 5D) than
when considering either group alone (Figures 5B and
5C). Similar results were obtained when the phosphopro-
teomes of our AML cell line panel were correlated with
resistance/sensitivity to JAK-i. Figure 6A shows the phos-
phopeptides with best correlation with the response to
this compound. While the combined intensities of the
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Figure 5 Correlating responses to MEK-i with protein phosphorylation data. The normalized intensities of phosphopeptides quantified
across seven AML cells were correlated with the responses to the inhibition of proliferation of cells exposed to 10 μM MEK-i, as measured by
cell viability. (a) Phosphopeptides showing greater correlation with resistance or sensitivity to MEK-i. (b) Correlation of the sum of the intensities
showing greater correlation with resistance. (c) Correlation of the sum of the intensities showing greater correlation with sensitivity. (d)
Correlation of the ratio between phosphopeptide intensities showing greater correlation to resistance relative to those showing greater
correlation with sensitivity. In each case, R refers to the Pearson correlation coefficient of the log2 transformed data; fold refers to the division of
the intensities of the peptide group increased in the most resistant cell line by that of the most sensitive cell line; open squares are individual
data points of three biological replicates; blue diamonds are the averages of the three replicates.
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phosphopeptides that correlated with resistance (group 1,
Figure 6B) or sensitivity (group 2, Figure 6C) showed
good correlation with viability (R = 0.89 and -0.95,
respectively), the ratio of group 1 to group 2 phospho-
peptide intensities showed the greater fold difference
between the most resistant and sensitive cell lines to
JAK-i (fold = 76.8), along with a strong linear correlation
of the semi-log transformed data (R = 0.94, Figure 6D).
To investigate whether phosphopeptides associated
with resistance/sensitivity in AML cells (Figures 4 to 6)
would also be associated with responses in other cell
types, we assessed whether these potential markers of
sensitivity would also correlate in lymphoma and multi-
ple myeloma cells shown in Figure 1. This analysis was
undertook with the view that not all sites associated with
responses in AML may be associated with the same para-
meters in lymphoma or multiple myeloma because of the
marked differences in phosphorylation across these
malignancies (Figure 1). First, sensitivity of the lym-
phoma and multiple myeloma cells shown in Figure 1 to
PI103, JAK-i, and MEK-i was determined using MTS
(Additional file 9, Figure S5A). These values of sensitivity
were then correlated withthe phosphorylation patterns of
the corresponding peptides previously found associated
to the inhibitors in the AML cells. Although not all
markers of sensitivity found for AML were also asso-
ciated with responses in lymphoma or multiple myeloma,
we found that the phosphorylation signals of PML p-
S506 and MARCKS p-S170 also positively correlate, with
viability after treatment with PI-103 in our set of lym-
phoma and multiple myeloma cells (R = 0.72 and 0.59,
respectively) (Additional file 9, Figure S5B). Similarly,
phosphorylation signals on KRT25 p-S7 and SKIV2L
p-T186 positively correlated with viability after treatment
with JAK-i (R = 0.63 and 0.78, respectively) while the
phosphorylation of HNRNPU p-272 negative correlated
with the viability after treatment with MEK-i (R = 0.97
and 0.82) (Additional file 9, Figure S5C and S5D). Thus
these data (Additional file 9, Figure S5) show that phos-
phorylation markers may be able to predict responses to
kinase inhibitors across different diseases despite their
marked differences in basal phosphorylation (Figure 1).
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Figure 6 Correlating responses to JAK-i with global protein phosphorylation. The normalized intensities of phosphopeptides quantified
across seven AML cells were correlated with the responses to the inhibition of proliferation of cells exposed to 1 μM JAK-i, as measured by cell
viability. (a) Phosphopeptides showing greater correlation with resistance or sensitivity to JAK-i. (b) Correlation of the sum of the intensities
showing greater correlation with resistance. (c) Correlation of the sum of the intensities showing greater correlation with sensitivity. (d)
Correlation of the ratio between phosphopeptide intensities showing greater correlation to resistance relative to those showing greater
correlation with sensitivity. In each case, R refers to the Pearson correlation coefficient of the log2 transformed data; fold refers to the division of
the intensities of the peptide group increased in the most resistant cell line by that of the most sensitive cell line; open squares are individual
data points of three biological replicates; blue diamonds are the averages of the three replicates.
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Pathways and ontologies associated with responses to
kinase inhibitors
In order to investigate pathways represented in phos-
phopeptide sets associated with the responses of our
AML cell line panel to kinase inhibitors, we performed
a bioinformatics analysis using DAVID pathway analysis
tools [35]. This analysis was based on phosphopeptides
correlating with responses with R > 0.45 or R < -0.45.
Phosphopeptides that correlated with the responses to
MEK-i and JAK-i were present in proteins with diverse
functions, including mRNA splicing, transcription and
nuclear proteins. PKC pathway members were signifi-
cantly enriched (P < 0.001) in the dataset of phosphory-
lation sites that correlated with the resistance to PI-103
(Additional file 10, Figure S6A). Ten phosphorylation
sites on kinases, six of which are Ser/Thr protein
kinases, were also found to correlate with resistance
(Additional file 10, Figure S6B). Phosphorylation sites
on proteins involved in transcription were well repre-
sented in the dataset that correlated with sensitivity to
PI-103 (Additional file 10, Figure S6C, although the
enrichment was not statistically significant, P= 0.2) or
with resistance (Additional file 10, Figure S6D).
To assess whether phosphorylation sites on known
members of PI3K, MEK, and JAK pathways would cor-
relate with the responses of our AML cell line panel to
the kinase inhibitors tested, we also specifically consid-
ered phosphorylation sites that, based on the literature,
are known to be downstream of these kinases. Phos-
phorylation sites on 4EBP1 (gene name EIF4EBP1) or
Ribosomal S6 (gene name RPS6), which are known to
be downstream of PI3K/mTOR(Ref [36]), did not corre-
late with the responses of our cancer cell panel to the
PI3K/mTOR inhibitor PI-103 (Figure 7A). In contrast, it
was interesting to observe that phosphorylation sites on
two phosphopeptides derived from MARCKS, which are
substrates of PKCs (Ref [37]) and which thus provide a
measure of PKC activities, correlated (R = 0.74 and
0.78) with the resistance of our AML panel to PI-103
(Figure 7B). These results are in line with those from
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Figure 7 Correlation of known PI3K, JAK and MEK pathway markers with responses to kinase inhibitors. (a) Correlation of
phosphorylated peptides containing phosphorylation sites known to be downstream of PI3K/mTOR with sensitivity to PI-103. (b) Correlation of
phosphorylated peptides on MARCKS, known to contain sites phosphorylated by PKCs, with responses to PI-103. (c) Correlation of
phosphorylation sites on STAT5A, a known JAK site, and ribosomal S6 (RPS6 gene product) with sensitivity to JAK-i. (d). Correlation of several
sites on stathmin (STMN1 gene product) with the sensitivity to MEK-i. Open squares: individual data points; filled diamonds: averages of
individual data points.
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the pathway analysis shown in Additional file 10, Figure
S6A suggesting a correlation between the phosphoryla-
tion of PKC pathway members and the resistance to
PI-103 and raised the hypothesis that PI-103 resistant
cells were using the PKC pathway to proliferate. To
explore this possibility, we treated P31/Fuj, HEL, and
MV4-11 cells with different combinations of the PI3K/
mTOR inhibitor PI-103 and the PKC inhibitor Go6976.
We found an additive effect of combining these com-
pounds in the viability of all these cell lines (Additional
file 11, Figure S7A). Interestingly, the cell lines with
greater concentrations of phosphorylated MARKCS (a
marker of PKC activity) were more resistant to the PKC
inhibition relative to those with low phospho-MARCKS
(Additional file 11, Figure S7B and S7C). These data are
in line with previous findings suggesting that the PKC
signaling pathway has a role in the proliferation and/or
survival of AML cell lines ([28]).
We also found that while the intensities of phosphory-
lated STAT5A, a marker of JAK activities, did not corre-
late with the responses of our AML cell panel to JAK-i,
the intensities of phosphorylated Ribosomal S6 (a mar-
ker of PI3K/mTOR pathway activation [36]) did corre-
late with resistance to this compound (Figure 7C). As
an example of a phosphoprotein that correlated with the
responses to MEK-i, Figure 7D shows the correlation of
several phosphorylation sites on Stathmin, alongside the
viability of cells exposed to this compound. The phos-
phorylation of S16, S38, and S63 on Stathmin followed
the same trend and had a relatively poor correlation
with the response to MEK-i (Figure 7D) compared to
the phosphorylation of S25, a site that can be phos-
phorylated by several MAP kinases and cyclin depen-
dent kinases [38,39]. Taken together, the data shown in
Figure 7 suggest that the activation of the pathway
being targeted did not in general correlate with the
response to kinase inhibitors and that phosphorylations
that correlate with responses predominantly were on
pathways parallel to those being targeted.
Phosphorylation motifs associated with responses to
kinase inhibitors
Phosphoprotein concentrations in cells can be a conse-
quence of the expression level of the phosphoprotein
bearing the site of modification as well as of the activity
of the kinases and phosphatases acting on these sites.
To investigate whether the phosphorylation sites that
correlated with resistance or sensitivity in this study
were the result of differential kinase activities across the
AML cell line panel or these were just a reflection of
phosphoprotein gene expression, we performed a further
bioinformatics analysis of the data aimed at assessing
common phosphorylation motifs in phosphopeptides
correlating with the responses to the inhibitors. In this,
phosphorylation motifs were obtained from the data
using motif-X [40] and from the literature [41]. The
normalized intensities of phosphorylation sites bearing
these motifs were then averaged and correlations with
the viability of cells to each inhibitor recalculated for
each of the averaged motif intensities. This analysis was
based on phosphopeptides with R > 0.45 or R < -0.45.
Figure 8 shows that phosphorylation motifs that corre-
lated with resistance were rich in basic residues and/or
had a proline at the carboxyl terminus of the phosphory-
lated residue. In contrast, phosphorylation motifs that
correlated with sensitivity to the inhibitors were predo-
minantly on acidic motifs for PI-103 and JAK-i (Figure
8A and 8C) or they contained a hydrophobic residue at
the N terminus for JAK-i and MEK-i (Figure 8B and 8C).
These data suggest that basophilic kinases (which include
the AGC family protein kinases such as S6K, PKC, PKA,
and PKB) and proline directed kinases (which include
mTOR, CDKs, and MAP kinases) may be more active in
resistant cells (Figure 8), whereas acidophilic kinases
(such as casein kinases) and hydrophobic amino acid
directed kinases (which include AMPK) may be more
active in sensitive cells. These data are consistent with
the correlation of PKC activity with resistance to PI-103
inferred from pathway and substrate phosphorylation
analyses (Figure 8 and Additional file 9, Figure S5) in that
the averaged intensities of 13 peptides containing the
preferred motif for PKC (xRxSx) and of eight peptides
containing the related xKxSx motif also correlated with
the resistance to PI-103 (Figure 8A). Also consistent with
the data shown in Figure 7C, suggesting a correlation
between S6K activity and the resistance to JAK-i, the
combined intensities of 43 phosphopeptides in the con-
text of the xRxxSx motif also correlated with the resis-
tance to this compound (Figure 8C). Of these, eight and
nine phosphopeptides were in the context of the
RxRxxSx and KxRxxSx motifs, respectively, which are the
preferred recognition motifs of S6K and related upstream
kinases such as PKB/Akt. Overall, the data in Figure 8
indicate that the correlation of phosphopeptide intensi-
ties with resistance and sensitivity to kinase inhibitors is
most likely due to differential kinase pathway activation
in these cells, rather than just reflecting differences in the
expression levels of the phosphoproteins bearing the sites
of modification.
Discussion
Tumor classification informs therapeutic strategies and
provides information on prognosis [42]. A classification
based on the likely response to a particular therapy may
be of particular importance in the use of agents that
target protein and lipid kinases in signaling pathways
[43]. These enzymes are drug targets deregulated in
essentially all cancers [8] but the lack of robust and
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generally applicable methods to stratify patients for
therapies based on kinase inhibitors limit their clinical
applicability [11]. DNA sequencing, expression arrays
and proteomic signatures have been used both to clas-
sify tumors and to indicate the presence of mutation
status or expression of genes involved in cancer cell sig-
naling [44-46]. However, protein, gene, or mRNA stu-
dies do not necessarily reflect enzyme activity, which
ultimately determines the activation status of signaling
pathways involved in cancer cell biology [5,6,47,48].
Protein phosphorylation is the result of the activities of
kinases present in the pathways that are being targeted
by signaling inhibitors and kinase activity is a major
determinant in conferring resistance/sensitivity to these
compounds. Therefore, it may be argued that a compre-
hensive analysis of protein phosphorylation might repre-
sent an ideal readout to classify tumors based on the
likelihood of response to inhibitors that target signaling
pathways.
In order to investigate whether phosphoproteomics may
be used to classify hematological cancers based on their
phenotype, and to provide proof-of-principle of the
approach, we analyzed the most abundant phosphopro-
teomes of nine hematological cancer cell lines. Qualitative
analysis of the data based on Gene Ontologies revealed
that our analysis was broad and included phosphopeptides
from all types of proteins, including those in cell mem-
branes, cytosol, and subcellular compartments. While
membrane proteins were slightly less represented than
expected, proteins involved in cell cycle regulation, prolif-
eration, and translation, and protein kinases were particu-
larly well represented in our phosphoprotein dataset.
As for the quantitative analyses, our data showed that
cancer cells of different phenotypes and origin had
markedly different patterns of phosphorylation, thus
indicating that phosphorylation could be used to classify
these cells according to phenotype. PCA and unsuper-
vised hierarchical clustering analysis classified cell lines
Mo?f/Replicate 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 n R
xxxxxRxSPxxxxxx
0 . 4 0 . 4 0 . 2 0 . 6 - 0 . 6 0 . 2 - 0 . 9 0 0 . 4 - 1 . 5 - 1 . 5 - 3 . 9 - 2 . 4 - 0 . 9 - 0 . 7 - 4 . 1 - 1 . 8 - 5 . 2 - 2 . 5 - 1 . 3 - 1 . 3
4 0.76
xxxxxRxSSxxxxxx
1 . 3 0 . 9 1 . 6 - 0 . 1 - 0 . 4 - 2 - 0 . 4 0 . 5 - 0 . 2 - 0 . 8 - 0 . 7 - 0 . 4 - 1 . 1 - 5 . 6 - 0 . 9 - 0 . 2 - 0 . 5 - 0 . 7 - 1 . 6 - 1 . 1 - 3 . 8
3 0.74
xxxxxPxSPxxxxxx
- 0 . 1 - 0 . 4 - 0 . 5 - 1 . 5 - 0 . 4 - 0 . 7 - 1 - 0 . 6 - 1 . 1 - 0 . 3 - 1 . 7 - 2 . 4 - 2 - 1 - 1 . 3 - 0 . 9 - 0 . 8 - 1 . 1 - 2 . 6 - 1 . 7 - 2 . 4
18 0.71
xxxxRRxSxSxxxxx
0 . 9 0 . 7 1 . 4 0 0 . 2 - 1 . 4 - 0 . 2 - 0 . 2 0 . 4 - 1 - 1 . 3 - 0 . 9 - 0 . 7 - 4 . 5 - 0 . 1 0 . 3 - 0 . 7 - 0 . 5 - 2 . 9 - 0 . 1 - 4 . 2
3 0.68
xxxxxxxSPxKxxxx
0 . 9 0 . 6 0 . 8 - 1 . 3 - 1 . 6 - 2 - 0 . 7 - 0 . 7 - 0 . 8 - 2 . 7 - 1 - 1 . 9 - 3 - 2 - 0 . 9 - 0 . 1 - 0 . 7 - 0 . 5 - 4 . 1 - 2 . 4 - 8 . 1
15 0.67
xxxxRxxSPxxxxxx
0 . 4 - 0 . 7 - 0 . 3 - 0 . 9 - 0 . 6 - 0 . 7 - 0 . 7 - 0 . 5 - 0 . 4 - 2 - 2 . 8 - 2 . 8 - 2 . 9 - 2 . 8 - 1 . 2 - 0 . 8 - 0 . 1 - 1 . 2 - 3 . 2 - 3 . 9 - 3
19 0.64
xxxxxxxSPxKxxKx
0 . 2 - 0 . 2 - 0 . 1 0 . 8 0 . 4 0 . 3 0 . 3 0 . 1 - 0 . 1 0 . 9 - 0 . 2 - 1 . 3 - 1 . 5 - 1 . 5 - 1 . 3 0 - 0 - 0 . 6 - 2 . 8 - 2 . 1 - 7 . 3
3 0.64
xxxxRxxSxxxxxxx
- 0 . 2 - 0 . 6 - 0 . 4 - 1 - 1 . 2 - 1 . 6 - 1 . 1 - 0 . 7 - 1 - 1 . 8 - 1 . 6 - 2 . 3 - 2 . 3 - 2 . 7 - 1 . 2 - 1 - 0 . 4 - 1 . 1 - 2 . 3 - 2 - 2 . 9
50 0.62
xxKRxxxSxxxxxxx
0 . 1 0 . 2 1 . 5 - 0 . 9 0 . 1 0 . 7 - 1 . 9 - 0 . 6 0 . 5 - 2 . 8 - 0 . 7 - 1 . 3 - 1 . 4 - 6 . 5 - 0 . 1 - 0 . 2 0 . 6 - 5 . 9 - 1 . 1 - 2 . 2 - 3 . 9
3 0.59
xxMxxxxSxxxxxxx
- 2 . 7 - 2 - 2 . 2 - 2 . 8 - 5 . 6 - 1 . 2 - 0 . 4 - 5 . 6 - 2 . 9 - 2 . 7 0 . 4 - 3 . 6 - 3 . 8 - 0 . 1 - 0 - 4 . 3 - 4 . 2 - 0 . 9 1 . 2 0 . 8 - 0 . 9
5 -0.52
xxxxFxxSxxxxxxx
- 3 . 3 - 2 . 3 - 1 . 5 - 1 . 5 - 1 . 1 - 1 . 5 - 1 . 1 - 1 . 4 - 1 . 4 0 . 7 - 0 - 0 . 4 - 0 . 1 - 0 . 8 - 0 . 1 - 1 . 4 - 1 . 3 - 1 . 5 1 . 1 - 0 . 2 0
7 -0.56
xxxxxxxSQxxxxxx
- 1 . 3 - 3 - 1 . 2 - 3 . 9 - 2 . 3 - 2 - 1 . 3 - 1 . 5 - 2 . 2 - 0 . 1 - 2 . 3 - 0 . 4 - 0 . 9 - 0 . 3 - 0 . 2 - 1 . 5 - 1 . 4 - 1 . 8 - 1 . 1 0 . 9 0 . 4
7 -0.59
xxxxxKxSxxxxxxx
- 3 . 6 - 2 . 9 - 1 . 4 - 1 . 6 - 2 . 2 - 1 - 0 . 3 - 1 . 6 - 1 . 6 - 0 . 7 - 1 . 5 - 1 . 8 - 1 . 1 - 1 . 1 - 1 - 1 . 3 - 1 . 5 - 1 . 1 0 . 1 0 . 5 - 0 . 7
16 -0.65
xxYxx
- 3 . 4 - 2 . 1 - 1 . 4 - 1 . 3 - 2 . 4 - 2 . 1 - 0 . 8 - 0 . 8 - 1 . 7 - 0 . 5 - 0 . 9 - 0 . 2 - 1 . 5 - 1 . 3 - 1 . 5 - 2 - 0 . 7 - 1 . 3 1 0 . 7 0 . 4
17 -0.66
Mo?f/Replicate 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 n R
xxxxxGxSxxxxxxx
1 . 2 4 1 . 1 8 0 . 7 5 - 0 . 3 0 . 5 7 0 . 1 2 0 . 0 8 - 0 - 0 . 9 - 0 . 4 0 . 4 8 0 . 3 4 0 . 0 1 - 1 . 2 0 . 2 - 0 . 4 0 . 1 - 1 . 4 - 2 . 9 - 2 . 2 - 2
10 0.83
xxxxxxxSPxxxxxx
0 . 9 6 1 . 1 1 0 . 4 4 - 0 . 4 0 . 0 7 - 0 . 1 0 . 4 7 0 . 3 8 0 . 5 1 - 0 . 9 - 0 . 7 - 0 . 3 - 0 . 1 - 0 . 2 - 0 . 7 - 1 . 5 - 1 - 0 . 7 - 2 . 4 - 2 . 2 - 1 . 1
60 0.80
xxxxxPxSPxxxxxx
1 . 2 6 1 . 3 8 0 . 8 9 0 . 4 6 0 . 3 8 - 0 . 4 - 0 . 4 0 . 3 0 . 4 7 - 1 . 7 - 2 . 2 - 1 . 1 - 0 . 8 - 0 . 8 - 1 . 1 - 2 . 2 - 1 . 7 - 1 . 1 - 3 . 4 - 2 . 5 - 0 . 5
19 0.794
xxxxxxxSPxKxxxx
0 . 7 1 . 5 3 1 . 5 2 0 . 6 8 - 0 . 7 1 . 2 1 0 . 6 - 0 . 9 0 . 7 8 - 0 . 6 - 0 . 6 - 0 . 9 - 1 . 1 - 0 . 2 - 1 . 3 - 1 . 3 - 1 . 6 0 . 0 3 - 2 . 2 - 1 . 8 - 1 . 2
7 0.76
xxxxxxxSPxxSxxx
2 . 8 4 2 . 7 1 2 . 3 3 0 . 1 0 . 1 7 0 . 0 5 - 2 0 . 0 9 0 . 0 1 - 1 . 4 - 1 . 7 - 0 . 6 - 0 . 5 - 0 . 1 - 0 . 4 - 2 . 3 - 2 . 2 - 0 . 5 - 2 . 8 - 2 . 7 - 1 . 9
8 0.72
xxKxxxxSxxxxxxx
0 . 5 0 . 7 3 0 . 3 4 - 0 . 7 0 . 3 1 - 0 . 7 0 . 3 6 0 . 3 2 - 0 . 1 - 0 . 2 - 0 . 6 - 0 . 3 0 . 3 1 - 1 . 4 - 0 . 4 0 . 1 7 0 . 2 7 - 1 - 2 . 5 - 2 - 1 . 8
21 0.68
xxxxGxxSPxxxxxx
2 . 9 4 2 . 6 4 2 . 7 3 - 1 . 6 - 1 . 1 - 1 . 4 0 . 4 3 - 0 . 5 - 0 . 1 - 0 . 5 0 . 5 1 - 0 - 0 . 3 0 . 6 3 - 0 . 5 - 2 . 5 - 0 . 1 - 2 . 1 - 3 . 6 - 3 . 4 - 1 . 3
12 0.68
xxxxxRxSxxxxxxx
1 . 8 3 2 . 2 4 1 . 8 6 - 0 0 . 2 2 - 0 . 8 - 0 0 1 . 5 1 0 . 7 - 1 0 . 6 7 0 . 1 - 0 . 5 0 . 9 9 - 0 . 2 - 0 . 2 - 1 . 3 - 1 . 2 - 1 . 7 0 . 0 1
13 0.67
xKxxxxxSPxxxxxx
0 . 6 2 0 . 9 6 0 . 5 1 0 . 7 6 0 . 5 3 - 0 . 5 0 . 6 3 0 . 7 8 0 . 3 5 - 2 . 4 - 2 - 2 . 3 - 0 . 9 - 1 . 1 - 0 . 5 - 2 . 8 - 2 - 0 . 9 - 2 . 7 - 3 . 5 - 0
12 0.67
xxxxxKxSxxxxxxx
0 . 0 5 0 . 6 2 0 . 2 2 - 0 . 2 - 0 . 2 - 0 . 1 0 . 3 7 - 0 . 1 0 . 3 - 2 - 0 . 3 - 0 . 1 0 . 1 4 - 0 . 6 0 . 5 4 - 0 . 9 - 2 - 0 . 1 - 0 . 6 - 2 . 3 - 1 . 2
8 0.61
xxxxRxxSPxxxxxx
- 0 . 1 1 . 3 1 0 . 2 6 0 . 6 3 1 . 2 8 0 . 9 6 0 . 7 4 0 . 7 4 0 . 9 4 - 0 . 6 - 1 . 2 - 1 . 3 - 1 . 4 - 0 . 7 - 0 . 9 - 1 . 9 - 1 . 1 0 . 3 5 - 2 . 5 - 0 . 8 - 0 . 7
7 0.61
xxxxxxxSxxxxDxx
- 2 . 4 - 1 . 4 - 2 . 4 - 1 . 2 0 . 6 7 - 1 . 4 0 . 6 3 0 . 9 2 0 . 9 7 0 . 0 4 - 2 0 . 3 0 . 5 7 - 2 . 6 - 0 . 1 - 0 . 4 - 0 - 2 . 6 0 . 3 9 0 . 6 8 0 . 8 2
6 -0.47
xxxxxxxSKxxxxxx
- 0 . 8 - 0 . 7 - 2 . 2 - 1 . 3 - 1 . 5 - 0 . 3 - 0 0 . 3 6 - 0 . 2 - 0 . 5 - 0 . 1 0 . 2 3 1 . 6 1 0 . 2 2 - 0 . 5 0 . 2 4 0 . 7 1 0 . 5 8 - 0 . 1 1 . 4 0 . 5 3
6 -0.60
xxxxxxxSDEExxxx
- 8 - 0 . 9 - 1 . 1 - 8 . 6 - 8 . 2 - 0 . 3 0 . 6 9 0 . 8 5 0 . 5 9 0 . 6 7 0 . 5 - 0 1 . 2 0 . 4 4 - 0 . 5 0 . 5 3 0 . 3 8 0 . 2 2 0 . 2 0 . 1 2 - 0 . 4
2 -0.46
xxxxxxxSxEExxxx
- 8 - 0 . 9 - 1 . 1 - 8 . 6 - 8 . 2 - 0 . 3 0 . 6 9 0 . 8 5 0 . 5 9 0 . 6 7 0 . 5 - 0 1 . 2 0 . 4 4 - 0 . 5 0 . 5 3 0 . 3 8 0 . 2 2 0 . 2 0 . 1 2 - 0 . 4
2 -0.46
xxxxxxxSxxxExEx
- 0 . 3 - 0 . 7 - 0 . 6 - 0 . 6 - 0 . 5 - 0 . 5 - 0 . 1 0 . 3 9 0 . 3 3 0 0 . 1 6 - 0 . 3 0 . 9 3 - 0 . 3 1 . 1 3 0 . 1 8 - 0 - 0 . 3 0 . 9 9 0 . 2 5 0 . 2
1 -0.52
xxxxxxDSDEDxxxx
0 . 0 7 - 0 - 0 . 6 - 0 . 9 - 0 . 4 0 . 1 5 - 0 . 2 - 0 . 2 0 . 1 2 0 . 4 4 - 0 . 2 - 0 . 9 0 . 3 - 0 . 3 - 1 . 7 0 . 4 4 0 . 5 0 . 1 1 . 1 2 0 . 8 7 0 . 4 1
2 -0.64
xxxxxxxSxEDxxxx
0 . 0 7 - 0 - 0 . 6 - 0 . 9 - 0 . 4 0 . 1 5 - 0 . 2 - 0 . 2 0 . 1 2 0 . 4 4 - 0 . 2 - 0 . 9 0 . 3 - 0 . 3 - 1 . 7 0 . 4 4 0 . 5 0 . 1 1 . 1 2 0 . 8 7 0 . 4 1
2 -0.64
Mo?f/Replicate 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 n R
xxKRxxxSxxxxxxx
1 1 1 1 1 1 - 0 - 0 - 1 - 1 - 1 - 1 - 0 - 1 - 7 0 - 0 0 - 8 - 0 - 0
2 0.78
xxxxxRxSSxxxxxx
1 1 1 - 0 - 0 - 0 0 1 - 0 - 1 - 1 - 2 - 0 - 1 - 1 - 0 - 0 - 0 - 7 - 1 - 6
3 0.73
xxxxxQxSPxxxxxx
1 1 1 - 0 0 - 1 - 1 - 0 - 1 - 2 - 1 - 0 - 2 - 1 - 0 - 0 - 1 - 1 - 2 - 1 0
2 0.67
xxKxRxxSxxxxxxx
1 2 1 - 4 - 3 - 4 - 2 - 1 - 0 - 2 - 2 - 4 - 3 - 3 - 3 - 4 - 4 - 2 - 7 - 4 - 3
9 0.64
xxxxRRxSxxxxxxx
1 1 1 - 3 - 2 - 3 - 0 - 0 - 0 - 0 - 1 - 5 - 1 - 3 - 1 - 3 - 3 - 1 - 4 - 6 - 4
5 0.64
xxxKRxxSxxxxxxx
1 1 1 - 5 - 4 - 1 - 1 - 1 - 0 - 4 - 3 - 8 - 2 - 2 - 4 - 1 - 0 - 1 - 6 - 4 - 1
4 0.61
xxxxxxxSPxKxxxx
- 0 1 2 - 2 - 5 - 2 # # - 3 - 7 - 7 - 5 - 5 - 5 - 4 - 7 - 3 - 7 - 3 - 5 - 7 - 8
5 0.60
xxKxxxxSxxxxxxx
- 0 - 1 - 1 - 2 - 2 - 3 - 2 - 2 - 2 - 2 - 3 - 4 - 3 - 3 - 3 - 2 - 3 - 1 - 4 - 4 - 2
21 0.60
xxRxRxxSxxxxxxx
0 1 0 - 2 - 1 - 0 - 2 - 2 - 1 - 4 - 2 - 5 - 3 - 1 - 2 - 0 - 0 - 0 - 6 - 2 - 3
8 0.60
xxxxRxxSxxxxxxx
- 1 0 - 0 - 2 - 2 - 2 - 2 - 1 - 1 - 3 - 2 - 3 - 2 - 1 - 2 - 2 - 2 - 1 - 3 - 2 - 2
43 0.56
xxxxxxxSDxExExx
- 7 - 1 - 7 - 0 - 0 - 1 - 1 - 0 - 5 1 1 1 - 0 - 0 - 0 0 - 0 - 0 0 1 0
2 -0.58
xxxxxxxSDxExxxx
- 5 - 2 - 5 - 2 - 1 - 1 - 0 - 0 - 3 1 1 0 - 1 - 0 - 0 - 1 0 0 0 1 - 4
4 -0.58
xxxxExxSxxxxxxx
- 1 - 4 - 4 - 5 - 7 - 7 - 3 - 1 - 3 - 1 - 1 - 6 - 1 - 4 - 4 - 8 - 1 - 2 1 0 - 0
5 -0.60
xxxxxxxSKxxxxxx
- 1 - 1 - 1 - 1 - 1 - 1 0 - 1 - 1 0 - 0 - 0 - 2 - 2 - 0 - 1 - 1 - 1 1 1 1
6 -0.64
xxxxxxxSxxExxxx
- 4 - 3 - 5 - 4 - 4 - 3 - 1 - 2 - 3 0 - 2 - 1 - 2 - 2 - 1 - 3 - 1 - 0 0 0 - 3
16 -0.66
xxLxxxxSxxxxxxx
- 2 - 2 - 2 - 4 - 3 - 3 - 2 - 2 - 3 - 1 - 1 - 2 - 2 - 2 - 2 - 2 - 1 - 1 0 0 - 0
21 -0.76
xRxxxxxSxxxxxxx
- 3 - 3 - 4 - 4 - 5 - 3 - 2 - 2 - 3 - 2 - 1 - 2 - 2 - 2 - 2 - 2 - 2 - 1 - 1 - 1 - 1
18 -0.76
xxxxxxxSDxxxExx
# # - 1 - 5 - 6 - 6 - 0 - 1 - 0 - 4 1 0 0 0 0 - 0 0 0 0 0 0 - 0
3 -0.77
xxxxKRxSxxxxxxx
- 2 - 2 - 2 - 6 - 5 - 6 0 0 0 - 0 - 1 1 - 0 0 - 1 - 3 - 0 - 1 1 1 1
3 -0.79
xxxWxxxSxxxxxxx
- 1 - 1 - 2 - 1 - 1 - 1 - 0 - 0 - 0 - 1 - 0 - 0 0 - 0 0 - 1 0 - 0 1 1 1
3 -0.87
MEK-i
PI-103 JAK-iP3
1/
Fu
j
H
EL
 
CM
K
KG
-1
M
V-
4-
11
Ka
su
m
i-1
AM
L-
19
3 
P3
1/
Fu
j
H
EL
 
CM
K
KG
-1
M
V-
4-
11
Ka
su
m
i-1
AM
L-
19
3 
P3
1/
Fu
j
H
EL
 
CM
K
KG
-1
M
V-
4-
11
Ka
su
m
i-1
AM
L-
19
3 
Proline containing 
Proline & basic
Basic
Acidic 
Hydrophobic
Other
Mo?f type:
(a)
(b)
(c)
Correlate 
with 
resistance
Correlate 
with 
sensi?vity
Correlate 
with 
resistance
Correlate 
with 
sensi?vity
Correlate 
with 
resistance
Correlate 
with 
sensi?vity
-5 -2 0 2 5
Fold (log2)
Figure 8 Phosphorylation motifs that correlate with the responses to kinase inhibitors. Phosphopeptides showing correlation to the
responses to kinase inhibitions were grouped based on these containing specific phosphorylation motifs. The intensities of phosphopeptides in
these groups were then averaged and correlated with viability of cells after exposure to PI-103, MEK-i, or JAK-i. Motifs were then ranked
according to their correlation to the responses to PI-103 (a), MEK-i (b), or JAK-i (c). Motifs were color-coded based on their type. R, Pearson
correlation to semi-log transformed data; n, number of phosphopeptides matched to the named motif.
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according to their pathology (AML, lymphoma, and
multiple myeloma), thus indicating that the phosphopro-
teomes of cells of the same pathology are more similar
than those derived from different diseases. Furthermore,
PC1 in the PCA and unsupervised hierarchical cluster-
ing clearly separated AML cells that have a myeloid
lineage from the other two diseases that have a
lymphoid lineage.
We evaluated the potential ability of phosphoproteo-
mics data in predicting drug response through a robust
cross-validation framework based on Lasso regression
analysis, showing that the phosphorylation levels of a
relatively small subset of phosphopeptides was informa-
tive with regard to treatment outcomes (Figure 3). In
addition, using a complementary approach based on a
correlation study, we identified phosphopeptide sets
whose combined intensities correlated with the responses
to the three compounds with remarkable correlation
coefficients (R = 0.99, 0.95, and 0.94 for the responses to
PI-103, MEK-i, and JAK-i, respectively). In addition to
observing strong correlations with cell viability, we also
found that the magnitude of changes between the phos-
phopeptide signatures of the most resistant and most
sensitive cells were greater, or close, to 100-fold in each
case (Figures 4F, 5D, and 6D). These large differences in
phosphopeptide intensities are noteworthy and important
as ideal predictors of response need to show robust dif-
ferences and steep slopes in the regression function in
addition to having a good correlation. Therefore, our
proof-of-concept study indicates that phosphoproteomics
may represent a general tool to identify biomarkers of
response to kinase inhibitors and to classify cancers
based on their likelihood that these respond to targeted
therapies. Although some peptides that predicted
responses to kinase inhibitors in AML were also asso-
ciated with responses to the same inhibitors in lym-
phoma and multiple myeloma cells, there were subsets of
phosphopeptides that predicted responses in AML cells
only. This could be attributed to the marked differences
in the patterns of basal phosphorylation between
lymphoma, multiple myeloma, and AML cells (Figure 1)
which may be a reflection of differences in the activity of
kinase signaling across these diseases.
The correlation between PI3K pathway activity markers
and sensitivity to PI3K compounds has been found to be
weak in recent studies [49,50]. For example, no correlation
between activating mutations on PIK3CA (the gene coding
for the PI3K catalytic alpha isoform) with responses to
PI3K inhibitors were found in cell lines [49], while a
recently reported clinical trial found that just 30% of breast
and gynecologic patients harboring PIK3CA mutations
responded to PI3K therapies [50]. Dan et al. found a weak
correlation between responses to PI3K inhibitors and
phosphorylation of Akt (R < 0.45 and fold < 10 [49]),
which is a marker of PI3K activity. Although the primary
aim of this work was not to identify mechanisms of resis-
tance, it was interesting to observe that, consistent with
the data in Dan et al. [49] and Alcolea et al. [28], the levels
of PI3K pathway activity markers did not correlate with
the responses of cancer cells to the PI3K inhibitor (Figure
7A). Similarly, phosphorylation of STAT5A, a marker of
JAK activity, did not correlate with the responses to JAK-i
(Figure 7C). Interestingly, the phosphorylation sites that
correlated with resistance were on pathways parallel to
those being targeted; that is, on sites phosphorylated by
PKC for the PI3K inhibitor (Figure 7B), thus raising the
hypothesis that pathways parallel to those being targeted
were contributing to resistance. The finding that in PKC
and PI3K inhibitors had additive effects in decreasing the
viability resistant AML cells (Additional file 10, Figure S6)
is consistent with this possibility.
Conclusion
Our data therefore suggest that the activity of pathways
parallel to those being targeted by the specific inhibitors
might contribute to intrinsic resistance to kinase inhibi-
tors, as observed in cells that acquired resistance as a
result to chronic exposure to compounds that target sig-
naling nodes [13,14,28,51,52].
Our analysis identified phosphorylation motifs that on
the whole correlated with resistance or sensitivity to
kinase inhibitors (Figure 8) indicating that different
kinases may be activated in resistant and sensitive cells.
Thus, it may be proposed that, in this study, unbiased
profiling of phosphorylation stratified AML cells based
on their responses to signaling inhibitors (Figures 3, 4,
5, 6, 7, 8) because these responses may be dependent on
a combination of active pathways (both target and paral-
lel) in cells, rather than on the activity of the target
kinase/pathway only. Therefore, the ability to quantita-
tively analyze protein phosphorylation without a precon-
ception of the pathways that may be implicated in
conferring sensitivity may represent an important
advance for therapies that target kinase signaling.
Materials and methods
Cell culture
Cell lines were obtained as indicated in Additional file 1,
Table S1 and Additional file 1, Table S2. All cell lines
were grown in RPMI-1640 media supplemented with
10% FBS and 100 units/mL penicillin/streptomycin at
37°C in a humidified atmosphere of 5% CO2. For experi-
ments, 10 x106 cells at 0.5 × 106 cells/mL were seeded
24 h before harvesting for each replicate.
Viability assay
Cell lines were seeded in 96-well plates and treated 24 h
later with 1 μM PI-103 (Calbiochem cat # 528100),
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10 μM MEK inhibitor I (referred as MEK-i hereafter,
Calbiochem cat # 444937), or 1 μM JAK inhibitor
(referred as JAK-i hereafter, Calbiochem cat # 420099)
for a further 72 h. Cell viability was assessed by MTS
assay (CellTiter 96® AQueousOne Solution Cell Prolif-
eration assay, Promega Corporation, Madison, WI,
USA).
Cell lysis, digestion, and solid-phase extraction
Cells were harvested by centrifugation at 300 × g for 5
min and washed twice with ice cold Dulbecco’s Phos-
phate Buffered Saline (DPBS) supplemented with 1 mM
Na3VO4 and 1 mMNaF. Cell pellets were lyzed with
1 mL denaturing buffer (8 M urea in 20 mM HEPES pH
8.0) supplemented with phosphatase inhibitors (1 mM
Na3VO4, 1 mMNaF, 1 mM b-glycerol phosphate,
1.25 mM sodium pyrophosphate) and further homoge-
nized by sonication (three pulses of 15 s). Cell debris
was removed by centrifugation (20,000 g for 5 min at
5°C), protein levels in the supernatant were quantified
by Bradford analysis and an aliquot containing 500 μg
of protein was diluted to a final volume of 1 mL in
denaturing buffer. Cysteines were reduced and alkylated
by sequential incubation with 4.1 mMdithiothreitol and
8.3 mMiodoacetamide for 15 min at room temperature
in the dark. Samples were diluted to a final concentra-
tion of 2 M urea using 20 mM HEPES (pH 8.0) and
proteins were digested with TLCK-Trypsin (20 TAME
units/mg) for 16 h at 37°C. Trypsin was removed by
centrifugation and the resultant peptide solutions
desalted by solid-phase extraction with Sep-Pak C18
columns (Waters UK Ltd, Manchester, UK) following
the manufacturer’s instructions.
Immobilized metal ion affinity chromatography (IMAC)
Phosphopeptides were enriched by IMAC using a
modified protocol previously described [24]. In brief,
Sep-Pak eluents were incubated for 1 h at room tem-
perature with 300 μL of equilibrated Fe(III) coated
sepharose beads used as 50% slurry in 50:50:0.1 aceto-
nitrile:water:TFA. For equilibration, beads were
washed twice with 200 mM EDTA, three times with
50:50:0.1 acetonitrile:water:TFA, incubated twice for
5 min at RT with 100 mM FeCl3 (same volume as
beads) and washed six times with 50% ACN/0.1% TFA.
Unbound peptides were discarded and beads were
sequentially washed with 300 μL of 50% acetonitrile/
0.1% TFA and 300 μL of 50% acetonitrile/1% TFA.
Phosphopeptides were recovered by incubating the
beads twice with 300 μL50% acetonitrile/1.5% ammo-
nia water pH 11.0 for 1 min, after which the recovered
solutions were pooled, acidified (by addition of 10%
formic acid), dried in a speedvac, and stored at -80°C
until analysis.
Nanoflow-liquid chromatography tandem mass
spectrometry (LC-MS/MS)
Phosphopeptides were resuspended in 0.1% TFA and
analyzed in a LC-MS/MS system in random order to
remove potential batch effects. Phosphoprotein separa-
tion was performed in a nanoflow ultra-high pressure
liquid chromatography system (nanoAcquity, Waters)
using a BEH 100 μm × 100 mm column (Waters) and a
binary mobile phase gradient with 0.1% formic acid in
LC-MS grade water (A) 0.1% formic acid in LC-MS
grade acetonitrile (solution B). Gradients used were as
follows: 1% B for 5 min, 1% B to 35% B over 100 min, a
5-min wash at 85% B, and a 7-min equilibration step at
1% B. The instrument delivered a flow rate of 5 μL/min
(loading) and 400 nL/min (gradient elution) with an
operating back pressure of about 3,000 psi. Phosphopep-
tides were directly eluted into an LTQ-Orbitrap XL mass
spectrometer (Thermo Fisher Scientific, Hemel Hemp-
stead, UK). This instrument acquired full scan survey
spectra (m/z 350-1,600) with a resolution of 60,000 at m/
z 400. A maximum of the five most abundant multiply
charged ions present in each survey spectrum were auto-
matically mass-selected in a data dependent manner,
fragmented by collision-induced dissociation (CID) (nor-
malized collision energy 35%), and analyzed in the LTQ.
Thus, full-MS scans were followed by a maximum of
5 MS/MS scans (m/z 50-2,000) resulting in a maximum
duty cycle of 2.5 s. For CID fragmentation multi-stage
activation was enabled. Because chromatographic peaks
were about 30 s at the base, these settings ensured that
there were at least 10 data points per extracted ion chro-
matogram (XIC). In the data dependent acquisition, a
dynamic exclusion was enabled with the exclusion list
restricted to 500 entries, exclusion duration of 40 s and
mass window of 10 ppm.
Identification and quantitation of phosphopeptides
For phosphopeptide identification, mascot Distiller 2.3.2
was used to smoothen and centroid the MS/MS data.
The processed files were searched against the human
sequence library in the SwissProt database (version
2010_03 containing 23,000 entries [53]) using the Mascot
search engine [54]. Searches were automated with Mas-
cot Daemon (v2.2.2; Matrix Science, London, UK). The
search parameters included the following parameters:
trypsin as digestion enzyme with two missed cleavages
allowed, carbamidomethyl (C) as fixed modification, and
Pyro-glu (N-term), Oxidation (M), and Phospho (STY) as
variable modifications. A mass tolerance of ± 7 ppm for
the precursor ion and ± 800 mmu for fragment ions was
allowed. Hits were considered significant when they had
an Expectation value of < 0.05 (as returned by Mascot).
False discovery rates were approximately 2% as deter-
mined by decoy database searches. Results from Mascot
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searches were deposited in to the ProteomeXchange
Consortium [55] via the PRIDE partner repository [56]
with the dataset identifier PXD000217 and DOI 10.6019/
PXD000217. Sites of modification were reported when
the Mascot delta score [57] was > 10; otherwise site
assignment was deemed ambiguous. Phosphopeptides are
reported in the results as gene name followed by phos-
phorylation site within the protein sequence and charge
of the measured ion.
Phosphopeptide quantification was performed as
described before [16,28]. Briefly, Pescal was used to align
the chromatograms of all samples to be analyzed, to con-
struct extracted ion chromatograms (XICs) for the first
three isotopes of each phosphopeptide ion selected for
quantitation, to pick the peaks to be quantified, and to
measure their peak height and area. Windows of molecular
mass and retention time were 7 ppm and 1.5 min, respec-
tively. The resulting quantitative data were parsed into
Excel files for further normalization and statistical analysis.
Phosphopeptide intensities were normalized to the total
chromatogram intensity and to the mean value across
samples.
PCA, clustering, and statistical analysis of MS data
To avoid interference from low intensity phosphopep-
tides that have the lowest quantification quality [16], a
peak intensity cut-off value was established. Thus, only
the phosphopeptides with a maximum intensity across
all samples above that cut-off were included in further
data analysis by principal component analysis (PCA) and
hierarchical clustering, both performed using R software
(v. 2.12.2). For this analysis, mass intensity data were log
transformed, peptides and arrays were normalized and
mean centered. Kendall’s tau coefficient was used to
measure the association between peptides and arrays.
Finally complete linkage clustering was applied to calcu-
late distances between clusters.
For stringent identification of differences across sam-
ples, phosphopeptides were considered differentially
phosphorylated between cell types when the Bonferroni-
corrected ANOVA and Tukey Pvalues were < 0.01 and
the fold difference was > 2. To correlate peptide phos-
phorylation with drug sensitivity, phosphopeptide inten-
sities derived from each cell line replicate were correlated
with their viability after drug treatment at either 1 μM or
10 μM relative to DMSO-treated control. The correlation
between relative phosphopeptide intensity and viability
was calculated using Pearson’s coefficient (R) of either
linear or logarithm transformed phosphorylation data.
LASSO regression analysis
Least absolute shrinkage and selection operator (Lasso)
regression is a multivariate variable selection technique
with a penalization approach that controls the number
of regressors to be included in the optimized model
[58]. This is achieved by including a ‘shrinkage’ para-
meter l in the cost function.
For each of the three drugs we considered a n x pma-
trix X (where n = number of biological samples (21 in
this study) and p = number of quantified phosphopep-
tides (2,135 in this study)) containing the column-wise
normalized (μ = 0, δ = 1) intensities of all the phospho-
peptides measured across the seven cell lines (three
measurements for each cell line).
We assessed the potential of these data in predicting
the level of resistance/sensitivity of the seven cell lines
to three kinase inhibitors through a ‘leave-one-cell-line-
out’ approach based on lasso linear regression. With this
method, seven different models were trained for each
drug, leaving out the three samples corresponding to
each of the seven cell lines, in turn. Then the trained
models were used to make predictions on the samples
that were left out in the corresponding training phase.
The predictive ability was evaluated in terms of correla-
tion between predicted and observed percentage of sur-
viving cells when compared to the negative control,
after the drug treatment.
For a given drug D, and a cell line C left out from the
training phase, let Y be the vector containing the 18 via-
bility scores (respectively for the remaining 18 samples)
and l a non-negative number. We solved through lasso
regression the problem:
minβ0,B
{
1
2n
∑n
i=1
(
yi − β0 − xTi B
)
+ λ
∑p
j=1
∣∣βj∣∣
}
(1)
where n is the number of observations (that is, the 18
samples from measurements on the remaining six cell
lines, in triplicate);yi is the viability score of sample i fol-
lowing treatment with D; xi is the row vector containing
the normalized intensities of the p phosphopeptides
when measured in the i-th sample; b0 and B are a scalar
and a p-vector, respectively. B contains the coefficients
of the regressors (that is, all the phosphopeptides) to be
optimized. As l increases, the number of non-zero com-
ponents (hence phosphopeptides with non-null coeffi-
cient in the model) decreases.
We determined the optimal value for the l parameter
with a three-fold cross-validation on the remaining 18
samples and solved equation (1) for vector B without
considering the samples of the left out cell line. In order
to reduce the instability of the final models across the
three-fold cross-validation used to determine l, these
two final steps were repeated 20 times (for each left-out
cell line) and the entries of the resulting B vector aver-
aged across these 20 iterations, ending up in the final
average model MD, C (that is, final model for drug D,
leaving out the cell line C samples). The frequency of
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observing a non-null coefficient for each regressor
across the 20 iterations (quantifying how much the cor-
responding phosphopeptide is stably included in the
optimal models) was also computed and reported in the
final results. The viability of each left-out cell line C was
finally predicted through the corresponding MD, C.
In order to make the values predicted through by MD,
C on the left-out samples across the seven different cell
lines C and the three drugs D comparable to each other,
these values were normalized (μ = 0, δ = 1) together
with the predictions of MD, C on the corresponding
training set. For the same reason, to produce the scatter
plot in Figure 3, all the observed viability were normal-
ized (μ = 0, δ = 1) drug-wisely.
To produce a final descriptive model MD* of response
to drug D, the coefficients of all the phosphopeptides
(and their non-null coefficient frequencies) were aver-
aged across the seven corresponding MD, C.
Phosphopeptides whose average non-null coefficient
frequency is > 50% in these final descriptive models are
those reported in the insets of Figure 3.
Bioinformatics
Proteins containing phosphopeptides that significantly
correlated with phenotypes were used for gene ontology
(GO) and pathway enrichment analysis using either an
in-house script that matched ontologies listed in Swis-
sProt to each gene product or by David analysis tools
[35]. As for phosphorylation motifs analysis, polypeptide
sequences were obtained from each phosphopeptide in
the dataset by leaving the phosphorylated residue in the
center of a sequence that was flanked by seven amino
acids on each side. In cases where the phosphorylated
residue in the original phosphopeptide had less than
seven amino acids at either terminus, these were
extended by blasting them against the SwissProt data-
base. Phosphorylation motifs were obtained from Motif-
X [40] and from the literature [41] to assemble a total
of 108 different motifs. Because no differences between
the rates at which Ser/Thr kinases phosphorylate Ser
and Thr residues have been reported, no distinction was
made between p-Ser and p-Thr containing motifs. Pep-
tides phosphorylated at tyrosines were grouped in a sin-
gle motif. Polypeptide sequences in the dataset were
matched to these phosphorylation motifs and the aver-
age of the normalized and log-transformed intensities of
all the phosphopeptides containing each of the pre-
defined phosphorylation motifs were then averaged and
correlated to sensitivity. A script in VBA was written to
automate the implementation of these algorithms.
Western blot
AML cell lines were seeded at 5 × 105 cells/mL. Cells
were harvested by centrifugation at 300 × g for 5 min,
washed twice with ice cold Dulbecco’s Phosphate Buf-
fered Saline (DPBS), supplemented with 1 mM Na3VO4
and 1 mMNaF. Cell pellets were lyzed with lysis buffer
(50 mMtris-HCL pH 7.4, 150 NaCL, 1 mM EDTA, 1%
Triton X-100. Protein concentration was calculated using
Bradford and 50 μg of protein were run in 10% SDS-
PAGE. Proteins were transferred to PVDF membranes
that were block with TBS-Tween (0.1%) supplemented
with 5% skim milk. Then membranes were incubated o/n
with primary antibody and secondary antibody for 1 h.
Protein bands were detected using ECL. Primary antibo-
dies pMARKS S153/156 (Cell Signaling: Cat.2741) and
Vinculin (Cell Signaling: Cat. 4650) were used at 1:1,000
and 1:10,000 dilution, respectively. Secondary antibodies
were used at 1:5,000 dilution.
Data availability
Mass spectrometry data have been deposited to the Pro-
teomeXchange with identifier PXD000217.
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